Trials / Completed
CompletedNCT00044148
The Effect of LY333531 on Protein in the Urine in Patients With Type 2 Diabetes
The Effect of LY333531 on Albuminuria in Patients With Type 2 Diabetes A Pilot Clinical Trial
- Status
- Completed
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- —
- Sponsor
- Chromaderm, Inc. · Industry
- Sex
- All
- Age
- 30 Years
- Healthy volunteers
- Accepted
Summary
The purpose of this study are to determine 1) Whether Ly333531 can reduce urinary albumin/creatinine excretion in patients with Type II diabetes and persistent albuminuria 2) Whether LY333531 reduces urinary TGF-B, 3) the safety of LY333531 and any side effects that may be associated with it.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | LY333531 |
Timeline
- Start date
- 2002-07-16
- Primary completion
- 2004-04-28
- Completion
- 2004-04-28
- First posted
- 2002-08-21
- Last updated
- 2017-02-01
Locations
15 sites across 1 country: United States
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT00044148. Inclusion in this directory is not an endorsement.